Overview

IDO2 Genetic Status Informs the Neoadjuvant Efficacy of Chloroquine (CQ) in Brain Metastasis Radiotherapy

Status:
Completed
Trial end date:
2013-08-01
Target enrollment:
0
Participant gender:
All
Summary
This research is being done to determine if a short course of Chloroquine (five weeks) before, during and after whole brain radiation therapy (WBRT) will improve the overall survival of subjects being treated for brain metastases.
Phase:
N/A
Accepts Healthy Volunteers?
No
Details
Lead Sponsor:
Main Line Health
Treatments:
Chloroquine
Chloroquine diphosphate
Criteria
Inclusion Criteria:

- Patients with histologically confirmed primary solid malignancy

- Patients with single or multiple brain metastases

- Patients with metastasis diameter < 5 cm

- Age > 18

- Clearance from the patient's physician that treatment with chloroquine should not pose
a problem to the patient

Exclusion Criteria:

- Patients with a history of hypotension, cardiomyopathy, epilepsy, seizures

- Patients with impaired renal function

- Patients with psoriasis, porphyria

- Patients with known hypersensitivity to 4-aminoquinoline compounds

- Pregnancy, nursing

- Prior radiotherapy

- During the chloroquine treatment, patients complaining from visual or auditory
disturbances, and patients suffering from acute gastrointestinal problems i.e.
Anorexia, nausea, vomiting, diarrhea, abdominal cramps